Narrowband UVB phototherapy for early-stage mycosis fungoides

Gathers, Raechele Cochran; Scherschun, Lubomira; Malick, Farah; Fivenson, David P.; Lim, Henry W.

doi:10.1067/mjd.2002.120911

Cited by 166 publications

(105 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,11,12,21,22 These rates of CR are also similar to those reported in patients treated with psoralen-UV-A 23-27 and more recently with narrow-band UV-B phototherapy. 28,29 Mean time to obtain CR in our study (3.6 months) was shorter than that reported in other series of the literature ( Table 2). The systematic use of topical corticosteroids may have been responsible for this short delay.…”

Section: Commentcontrasting

confidence: 55%

Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids

Quatrebarbes

Estève²,

Bagot³

et al. 2005

Arch Dermatol

View full text Add to dashboard Cite

Section: Commentcontrasting

confidence: 55%

Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids

Quatrebarbes

Estève²,

Bagot³

et al. 2005

Arch Dermatol

View full text Add to dashboard Cite

“…Şikayetlerin başladığı tarih ile tedavinin (fototerapi) baş-ladığı tarih arası sürenin tedavi sonucuna etki etmediğini bildiren yayınların yanı sıra, bu sürenin uzun olmasının tedavi başarısını azaltacağını bildiren yayınlar da mevcuttur (15,16). Hastalarımızın sonuçları TR'a ulaşma oranı, TR'a ulaşma süresi, nüks oranları ve remisyonda kalma süreleri açısından gruplar arasında anlamlı fark olmadı-ğını göstermekteydi (Tablo 8).…”

Section: Discussionunclassified

Mikozis fungoides tedavisinde dbUVB ve PUVA: Retrospektif de- ğerlendirme

Ünal¹,

Tol²,

Balevi³

2015

GenelTipDer

View full text Add to dashboard Cite

Mikozis fungoides tedavisinde dbUVB ve PUVA -Unal ve ark.Genel Tıp Derg 2015;25:89-94 89 GirişMikozis fungoides (MF); tüm primer kutanöz lenfomaların %50'sini oluşturur ve kutanöz T hücreli lenfomaların (KTHL) en sık görülen tipidir (1-3). MF genellikle yaşlı nüfusu (en sık 40-60 yaş arası) etkilemekle beraber çocuk ve gençlerde de görülebilir. MF'in etiyolojisi ve patogenezi tam olarak bilinmemektedir. Klasik MF; yama evresinden başlayıp plak ve tümöral evreye kadar gidebilen uzun ve yavaş bir seyir gösterir (4-6).Erken evre MF; sistemik tutulumun görülmediği sınırlı ya da geniş alanlarda yerleşebilen eritemli, hafif skuamlı yama veya plaklarla karakterizedir (Evre IA, IB, IIA). MF tedavisinde fototerapinin etkili olabileceği fikri lezyonların özellikle güneş görmeyen alanlarda ortaya çıktığının gözlenmesiyle ortaya atılmış ve ilk olarak genişband UVB kullanılmış; daha sonra da psoralenli UVA (PUVA) ve NB-UVB and PUVA in mycosis fungoides therapy: A retrospective studyObjectives: The efficiency of narrowband UVB (NB-UVB) and psoralen+UVA ( PUVA) in treatment of MF was evaluated. Material and methods: Sixy-one patients diagnosed with MF treated with NBUVB or PUVA were studied retrospectively. Gender, age, time of diagnose, duration from initial lesion/lesions to diagnose and treatment, lypmhadenopathy, MF stage, phototherapy regime, systemic agents, mean time to complete remission (CR), mean number of treatment to CR, mean irradiation dose to CR, mean duration of maintenance therapy, mean relapse-free interval, relapse rate, total follow-up duration, advers effects during treatment and comorbidities obtained from patients dermatological charts were recorded. Results: Our results indicate that NB-UVB and PUVA have similar conclusions in treatment of early-stage MF. Mean time to CR and mean duration from CR to relapse were shorter for patients who treated with NB-UVB than PUVA group. CR rate was lower in stage 2A. Combination of systemic agents with phototherapy did not have a statistically significant impact as expected. Conclusion: At the end of the our study, we observed that NB-UVB and PUVA are usefull and have acceptably good results in patients with early-stage MF. Mean time to CR and mean duration from CR to relapse were shorter for NB-UVB group.

show abstract

“…Psoralen, which forms DNA adducts upon photoactivation, combined with ultraviolet A (PUVA) causes tumor cell apoptosis and is associated with a complete response rate exceeding 90%, and a prolonged disease-free interval, in patients with stage IA/IB disease [212,213]. In contrast to PUVA, use of either broadband or narrowband ultraviolet B (UVB) does not require psoralen and is associated with a high clinical and pathologic complete response rate, particularly for patients with patch-stage disease [214][215][216][217][218]. Malignant T cells are radiosensitive.…”

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Narrowband UVB phototherapy for early-stage mycosis fungoides

Cited by 166 publications

References 21 publications

Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids

Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids

Mikozis fungoides tedavisinde dbUVB ve PUVA: Retrospektif de- ğerlendirme

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Contact Info

Product

Resources

About